Skip to content

Immune Cell Dysfunction in Severe Alcoholic Hepatitis

Immune Cell Dysfunction in Severe Alcoholic Hepatitis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02275195
Enrollment
50
Registered
2014-10-27
Start date
2013-11-30
Completion date
2024-12-31
Last updated
2024-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis

Keywords

hepatitis, alcohol

Brief summary

Through bio-sampling this study investigates the relationship between the frequency and function of the cells of a patients immune system and how these change and impact on the outcome of alcoholic hepatitis. the investigators will examine the role of different cells of the immune system and how they may determine the outcome of this condition. The investigators will also look at how established treatment strategies impact on the frequency and function of these cell subsets.

Detailed description

Through bio-sampling this study investigates the relationship between the frequency and function of the cells of a patients immune system and how these change and impact on the outcome of alcoholic hepatitis. The investigators will examine the role of different cells of the immune system and how they may determine the outcome of this condition. The investigators will also look at how established treatment strategies impact on the frequency and function of these cell subsets. Alcohol is the most common cause of liver disease in the developed world and results in the death of 2.5 million people annually. It is a causal factor in more than 60 major types of diseases and injuries and approximately 4.5% of the global burden of disease and injury is attributable to alcohol. Acute alcoholic hepatitis (AAH) is perhaps the most florid form of ALD and the leading cause of mortality in these patients is the development of sepsis which occurs in up to 40% of these patients and has a mortality rate of 50%. By gaining a better understanding of the relationship between elements of the immune system and the progression to severe alcoholic hepatitis, it will allow the formulation of more effective treatment strategies for this condition. Patients who agree to participate in this study will have an extra 40mls of blood drawn for scientific studies at the same time as routine blood samples are taken as part of their ongoing care.

Interventions

None listed

Sponsors

Mid and South Essex NHS Foundation Trust
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Age 18-65 years 2. Patients presented with severe alcoholic hepatitis with a Maddrey score (discriminant function) of \>32 (The Maddrey score uses various blood results on a patient to define the severity of alcoholic hepatitis e.g.bilirubin etc). 3. Ongoing abuse of alcohol (drinking in excess of 28 units/wk)

Exclusion criteria

1. Co-infection with HIV/Hepatitis B / Hepatitis C virus infection. 2. Patients with autoimmune liver disease. 3. Patients with metabolic liver disease. 4. Patients with significant psychiatric and/or neurological co-morbidity. 5. Hepatocellular carcinoma or other neoplastic disease 6. Pregnancy or breast feeding of infants.

Design outcomes

Primary

MeasureTime frameDescription
To determine and changes to immune cell responses for outpatients with Alcoholic HepatitisParticipants will be followed-up during thier hospital stay, which averages 4 weeksCharacterize the relationship between various elements of patients immune system and the progression of an episode of severe Alcoholic Hepatitis

Secondary

MeasureTime frameDescription
Change from baseline to end of study in flow cytometry for patients with Alcoholic Hepatitison average 4 weeksCharacterize the relationship between various elements of patients immune system and the progression of an episode of severe Alcoholic Hepatitis
Change from baseline to end of study in real time PCR for patients with Alcoholic HepatitisOn average 4 weksCharacterize the relationship between various elements of patients immune system and the progression of an episode of severe Alcoholic Hepatitis
Change from baseline to end of study in cell cultures for patients with Alcoholic Hepatitison average 4 weeksCharacterize the relationship between various elements of patients immune system and the progression of an episode of severe Alcoholic Hepatitis

Countries

United Kingdom

Contacts

Primary ContactCarol L Alves, BSc, MRes
Carol.Alves@btuh.nhs.uk01268 529400

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026